| __timestamp | Apellis Pharmaceuticals, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 72429000 |
| Thursday, January 1, 2015 | 6356782 | 78634000 |
| Friday, January 1, 2016 | 4303743 | 75374000 |
| Sunday, January 1, 2017 | 10463151 | 92157000 |
| Monday, January 1, 2018 | 22639184 | 93326000 |
| Tuesday, January 1, 2019 | 67046483 | 103132000 |
| Wednesday, January 1, 2020 | 139401000 | 110171000 |
| Friday, January 1, 2021 | 176771000 | 218817000 |
| Saturday, January 1, 2022 | 277163000 | 233827000 |
| Sunday, January 1, 2023 | 500815000 | 267194000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Lantheus Holdings, Inc. and Apellis Pharmaceuticals, Inc. have shown contrasting approaches over the past decade.
Lantheus has maintained a relatively stable SG&A expense trend, with a modest increase of about 270% from 2014 to 2023. This steady growth reflects a disciplined approach to cost management, ensuring that expenses align with revenue growth.
In contrast, Apellis has experienced a dramatic surge in SG&A expenses, skyrocketing by over 17,000% during the same period. This sharp increase suggests aggressive expansion strategies, possibly investing heavily in marketing and administrative capabilities to capture market share.
Both companies illustrate different strategies in managing SG&A costs, offering valuable insights into their operational priorities and market strategies.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Apellis Pharmaceuticals, Inc.
Ascendis Pharma A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE